1253197-28-2

Upstream product

• 2645-02-5 methyl tosylglycinate 
• 177259-98-2 2-[(3-(benzyloxy)phenyl)]ethan-1-ol 
• 2039-67-0 2-(3-methoxyphenyl)-1-ethanamine 
• 98-59-9 p-toluenesulfonyl chloride 
• 64880-89-3 N-[(3-methoxyphenyl)ethyl]-4′′-methylbenzenesulfonamide 
• 81593-57-9 7-methoxy-3-(4-methylphenylsulfonyl)-2,3,4,5-tetrahydro-3-benzazepin-1-one 
• 81593-56-8 [[2-(3-Methoxy-phenyl)-ethyl]-(toluene-4-sulfonyl)-amino]-acetic acid 
• 1253197-27-1 7-hydroxy-3-(4-tosyl)-2,3,4,5-tetrahydro-3-benzazepine-1-one 
• 100-39-0 benzyl bromide 

Downstream Products

• 1253197-29-3 (+/-)-7-benzyloxy-3-(4-tosyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-1-ol 
• 1253197-26-0 (+/-)-7-benzyloxy-2,3,4,5-tetrahydro-1H-3-benzazepin-1-ol 
• 1253197-30-6 (+/-)-WMS-1418 
• 1253197-31-7 (+/-)-7-benzyloxy-3-[3-(phenylsulfonyl)propyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-1-ol 
• 1253197-32-8 (+/-)-7-benzyloxy-3-[3-(phenylsulfanyl)propyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-1-ol 
• 1253197-33-9 (+/-)-7-(benzyloxy)-3-(3-[2-(4-fluorophenyl)-5,5-dimethyl-1,3-dioxan-2-yl]propyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-1-ol 
• 1253197-34-0 (+/-)-trans-7-(benzyloxy)-3-(4-phenylcyclohexyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-1-ol 
• 1253197-35-1 (+/-)-cis-7-(benzyloxy)-3-(4-phenylcyclohexyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-1-ol 
• 1257108-44-3 (+/-)-7-(benzyloxy)-3-(3-phenylbenzyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-1-ol 
• 1253197-37-3 (+/-)-7-benzyloxy-3-(1,4-dioxaspiro[4.5]decan-8-yl)-2,3,4,5-tetrahydro-1H-3-benzazepin-1-ol 
• 1253197-38-4 (+/-)-WMS-1410 
• 1253197-39-5 (+/-)-N-benzyl-2-[7-(benzyloxy)-1-hydroxy-2,3,4,5-tetrahydro-1H-3-benzazepin-3-yl]-N-methylacetamide 

Relevant academic research and scientific papers

Fluorinated GluN2B Receptor Antagonists with a 3-Benzazepine Scaffold Designed for PET Studies

To analyze the N-methyl-d-aspartate (NMDA) receptor distribution in the central nervous system, fluorinated ligands that selectively address the ifenprodil binding site of GluN2B-subunit-containing NMDA receptors were developed. Various strategies to introduce a fluorine atom into the potent GluN2B ligand 2 (3-(4-phenylbutyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-1,7-diol) were pursued, including replacement of the benzylic OH moiety with a fluorine atom (13) and introduction of fluoroethoxy moieties at various positions (14 (7-position), 17 (9-position), 18a–c (1-position)). With respect to GluN2B affinity and selectivity over related receptors, the fluoroethoxy derivatives 14 and 18a are the most promising ligands. Radiosynthesis of fluoroethoxy derivative [18F]14 was performed by nucleophilic substitution of the phenol 2 with 2-[18F]fluoroethyl tosylate. On rat brain slices the fluorinated PET tracer [18F]14 accumulated in regions with high density of NMDA receptors containing GluN2B subunits. The bound radioactivity could not be replaced by (S)-glutamate. However, the GluN2B ligands eliprodil, Ro 25-6981, and the non-labeled 3-benzazepine 14 were able to abolish the specific binding of [18F]14.

BENZAZEPIN-1-OL-DERIVED PET LIGANDS WITH HIGH IN VIVO NMDA SPECIFICITY

The present invention is directed to benzazepin-1-ol-derived compounds for use in the diagnosis of NMDA receptor-associated diseases or disorders by positron emission tomography (PET). The invention also relates to a method for the diagnosis of NMDA-receptor-associated diseases or disorders by administering to a patient in need of such diagnosis a radioactively labelled compound of the invention in an amount effective for PET imaging of NMDA receptors, recording at least one PET scan, and diagnosing an NMDA-receptor-associated disease or disorder from an abnormal NMDA receptor expression pattern on the PET scan. NMDA-receptor-associated diseases or disorders that can be diagnosed with the radioactively labelled benzazepin-1-ol-derived compounds include but are not limited to neurodegenerative diseases or disorders, Alzheimer's disease, depressive disorders, Parkinson's disease, traumatic brain injury, stroke, migraine, alcohol withdrawal and chronic and neuropathic pain.

NR2B SELECTIVE NMDA-RECEPTOR ANTAGONISTS FOR TREATMENT OF IMMUNE-MEDIATED INFLAMMATORY DISEASES

The present invention provides novel means and methods for treatment auf immunemediated inflammatory diseases.

Conformationally constrained NR2B selective NMDA receptor antagonists derived from ifenprodil: Synthesis and biological evaluation of tetrahydro-3-benzazepine-1,7-diols

NR2B selective NMDA receptor antagonists with tetrahydro-3-benzazepine-1,7- diol scaffold have been designed by formal cleavage and reconstitution of the piperidine ring of the lead compound ifenprodil (1). The secondary amine 10 represents the central bu

NR2B-SELECTIVE NMDA-RECEPTOR ANTAGONISTS

The present invention relates to compounds according to general formula (I) and pharmaceutical compositions comprising compounds according to general formula (I).